top of page
SwanBio Therapeutics aims to bring life-changing treatments to people with devastating, inherited neurological conditions. The company is advancing a pipeline of gene therapies designed to be delivered intrathecally to address targets within both the central and peripheral nervous systems. SwanBio’s lead program is the first clinical-stage AAV-based gene therapy for the treatment of adrenomyeloneuropathy (AMN).
For more information, visit swanbiotx.com.
bottom of page